Catalys Pacific, LLC
CIK 2011385 · View on SEC EDGAR ↗
- Portfolio value
- $229.5M
- Positions
- 2
- As of
- June 30, 2026
Portfolio value QoQ: -0.5% 13F does not disclose cash
- Top 10 holdings weight
- 100.00%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 2
- Effective number of positions
- 1.2
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 0.0% Est. buys $0 · sells $0
Median holding: 7.0 quarters Tracked Q4 2024–Q2 2026 · 100.0% still held
- New positions
- 0
- Increased
- 0
- Decreased
- 0
- Closed
- 0
On this page
Performance vs S&P 500
Annualized: +65.1% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 100.0% · Options excluded: 0.0%
Sector breakdown
Full portfolio 2 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics, Inc. - Common Stock | $213,245,549 | 92.94% | 7,903,838 | $-869,422 | |||
| PHAT Phathom Pharmaceuticals, Inc. - Common Stock | $16,208,316 | 7.06% | 1,493,854 | $-388,402 | |||
| No matches | |||||||